NASDAQ:VERU
Veru Stock News
$0.700
+0.0535 (+8.27%)
At Close: Mar 28, 2024
The 3 Best Penny Stocks to Buy in February 2024
07:49am, Thursday, 15'th Feb 2024
Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecosystem of co
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)
10:36am, Tuesday, 13'th Feb 2024
The heavy selling pressure might have exhausted for Veru Inc. (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts
Veru Inc. (VERU) Q1 2024 Earnings Call Transcript
01:36pm, Thursday, 08'th Feb 2024
Veru Inc. (VERU) Q1 2024 Earnings Call Transcript
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
08:30am, Wednesday, 31'st Jan 2024
MIAMI, FL, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for obesity, oncology, and viral induced ac
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
08:30am, Thursday, 25'th Jan 2024
MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and
Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023
08:30am, Wednesday, 20'th Sep 2023
MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral
Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023
08:30am, Wednesday, 30'th Aug 2023
MIAMI, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral indu
Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates
09:15am, Thursday, 10'th Aug 2023
Veru Inc. (VERU) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.28 per share a year ago.
Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023
08:30am, Thursday, 03'rd Aug 2023
MIAMI, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for breast cancer and for viral acute respi
Veru to Present at the Jefferies Healthcare Conference
08:30am, Wednesday, 24'th May 2023
MIAMI, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for S
Veru Inc. (VERU) Q1 2023 Earnings Call Transcript
03:28pm, Thursday, 11'th May 2023
Veru Inc. (NASDAQ:VERU ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations & Corporate Communications Mitchell Steiner -
Veru Inc. (VERU) Reports Q2 Loss, Tops Revenue Estimates
09:10am, Thursday, 11'th May 2023
Veru Inc. (VERU) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.18 per share a year ago.
VERU Stock Earnings: Veru Misses EPS, Beats Revenue Estimates
08:09am, Thursday, 11'th May 2023
Veru (NASDAQ: VERU ) just reported its fiscal second-quarter results. Veru reported a loss per share of 43 cents.
Is a Surprise Coming for Veru (VERU) This Earnings Season?
01:01pm, Tuesday, 09'th May 2023
Veru (VERU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023
06:45am, Thursday, 27'th Apr 2023
MIAMI, FL, April 27, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related disea